SNHG19: A Drug Target / Disease Biomarker (G100507303)

Target Name: SNHG19

NCBI ID: G100507303

SNHG19

Other Name(s): small nucleolar RNA host gene 19 | SNORD60HG | Small nucleolar RNA host gene 19

SNHG19: A Drug Target / Disease Biomarker

SNHG19 is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The gene is located on chromosome 6 and encodes for a protein known as solute carrier family 19 member 1 (SLC19F1).

SLC19F1 is a protein that is expressed in many different tissues and cells in the body, including the brain, heart, kidneys, and liver. It is involved in the transport of a variety of molecules, including ions, nutrients, and medications.

One of the key functions of SLC19F1 is its role in the regulation of blood pressure. The protein helps to transport nutrients and ions across the blood-brain barrier, which is a barrier that separates the brain from the rest of the body. This is important for maintaining the proper functioning of the brain and for ensuring that it receives the necessary nutrients and oxygen.

In addition to its role in blood pressure regulation, SLC19F1 has also been shown to be involved in the development and progression of certain diseases. For example, studies have suggested that high levels of SLC19F1 may be associated with an increased risk of developing cancer. Additionally, the protein has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

As a potential drug target, SLC19F1 is being studied for its potential to treat a variety of diseases. For example, researchers have found that SLC19F1 is involved in the development of neurodegenerative diseases, and they are investigating the use of drugs that can inhibit its activity to treat these conditions. Additionally, SLC19F1 has also been shown to be involved in the regulation of blood pressure, and researchers are investigating the use of drugs that can target this protein to treat hypertension.

In conclusion, SNHG19 is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases. The protein is involved in the regulation of blood pressure and has also been shown to be involved in the development and progression of certain diseases, including cancer and neurodegenerative diseases. Further research is needed to fully understand the potential of SLC19F1 as a drug target or biomarker.

Protein Name: Small Nucleolar RNA Host Gene 19

The "SNHG19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNHG19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets